Roche has signed an agreement to acquire Innovatis, a German-based provider of automated cell analysis solutions, for $19.4 million. Innovatis will become a fully-integrated part of Roche Applied Science, the company’s diagnostic division. Innovatis will develop and market products for cell analysis through Roche’s worldwide network. The transaction is expected to close within the next few weeks.
"This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market,” said Dr. Jürgen Schwiezer, chief executive officer, Roche Diagnostics. “Innovatis’ technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008.”
Michael Grohmann, chief executive officer of the Innovatis AG stated “Roche has been one of our key customers for many years, in particular since the successful development of our cell analysis technology over 10 years ago. The Innovatis technology is very well placed for future growth as part of Roche Applied Science.”
